# A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

> **NCT04875195** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 66 (actual)

## Conditions studied

- Hodgkin's Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04875195
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-07
- **Primary completion:** 2023-12-14
- **Final completion:** 2025-10-13
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04875195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04875195, "A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04875195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*